Cited by 134Antifungal resistance and susceptibilityAntibiotics Pharmacokinetics and EfficacyFungal Infections and Studies

In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model

Open access
Andes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K., Bohrmueller, J.·2008·Antimicrobial Agents and Chemotherapy

Abstract

Previous studies using in vivo candidiasis models have demonstrated that the concentration-associated pharmacodynamic indices, the maximum concentration of a drug in serum/MIC and 24-h area under the curve (AUC)/MIC, are associated with echinocandin treatment efficacy. The current investigations used a neutropenic murine model of disseminated Candida albicans and C. glabrata infection to identify the 24-h AUC/MIC index target associated with a stasis and killing endpoint for the echinocandin, micafungin. The kinetics after intraperitoneal micafungin dosing were determined in neutropenic infected mice. Peak levels and AUC values were linear over the 16-fold dose range studied. The serum drug elimination half-life ranged from 7.5 to 16 h. Treatment studies were conducted with 4 C. albicans and 10 C. glabrata isolates with micafungin MICs varying from 0.008 to 0.25 μg/ml to determine whether similar 24-h AUC/MIC ratios were associated with efficacy. The free drug AUC/MICs associated with stasis and killing (1-log) endpoints were near 10 and 20, respectively. The micafungin exposures associated with efficacy were similar for the two Candida species. Furthermore, the free drug micafungin exposures required to produce stasis and killing endpoints were similar to those recently reported for another echinocandin, anidulafungin, against the identical Candida isolates in this model.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.00478-08

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PK/PD studies with echinocandins demonstrate concentration-dependent activity with a prolonged PAFE similar to that observed with amphotericin B.

    “PK/PD studies with the echinocandin class of antifungals demonstrate concentrationdependent activity with a prolonged PAFE similar to that observed with amphotericin B.”
  • The concentration-dependent indices Cmax/MIC and AUC/MIC are both closely linked to efficacy for echinocandins and support administration of large infrequent doses.

    “The concentration-dependent indices, C max /MIC and AUC/MIC, are both closely linked to efficacy and support administration of large infrequent doses.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 6

  1. [6]Andes, D. 2001. In vivo pharmacodynamics of amphotericin B against selected Candida species. Antimicrob. Agents Chemother. 45:922-926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. [10]Buell, D., L. Kovanda, T. Drake, et al. 2007. Alternative day dosing of micafungin in the treatment of esophageal candidiasis, abstr. M719. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
  3. [14]Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12. [DOI] [PubMed] [Google Scholar]
  4. [30]Martinez, M., and D. A. Stevens. 2006. Bioassay for azoles in the presence of caspofungin and visa versa, abstr. A2076. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
  5. [46]Vazquez, J. A., and J. D. Sobel. 2006. Anidulafungin: a novel echinocandin. Clin. Infect. Dis. 43:215-222. [DOI] [PubMed] [Google Scholar]
  6. [51]Yamato, Y., H. Kanedo, T. Hashimoto, M. Katashima, K. Ishibashi, A. Kawamura, M. Terakawa, and A. Kagayama. 2002. Pharmacokinetics of the antifungal drug micafungin in mice, rats, and dogs and in its in vitro protein binding and distribution to blood cells. Jpn. J. Chemother. 50:74-79. [Google Scholar]

Cited by

Sorted by citations

Authors
Andes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K., & Bohrmueller, J.
Affiliations
  • University of Wisconsin–Madison (US)
  • University of Iowa (US)
  • Department of Medicine
Corresponding author
Andes, D. R.
Venue
Antimicrobial Agents and Chemotherapy
Published
2008-10
Volume
52
Issue
10
Pages
3497-3503
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2147530964
Cited by
134
References
48
Citations by year
2026: 2 · 2025: 4 · 2024: 5 · 2023: 5 · 2022: 2 · 2021: 6 · 2020: 6 · 2019: 4 · 2018: 6 · 2017: 11 · 2016: 11 · 2015: 10 · 2014: 8 · 2013: 5 · 2012: 5
FWCI
9.48
Type
journal article
Language
en
Open access
Locations
  • Antimicrobial Agents and Chemotherapy (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Astellas Pharma
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Pharmacology › Antibiotics Pharmacokinetics and Efficacy
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Keywords
micafungin, echinocandins, Candida albicans, Candida glabrata, therapeutic target, AUC/MIC ratio, drug exposure, antifungal efficacy, pharmacokinetics, elimination half-life, anidulafungin, systemic candidiasis
MeSH terms
Micafungin, Animals, Antifungal Agents, Candida albicans, Candidiasis, Disease Models, Animal, Female, Mice, Inbred ICR, Neutropenia, Colony Count, Microbial, Candida glabrata, Mice, Echinocandins, Lipopeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review